Pharmaceuticals

Synthetic Lethality: Q&A with Oren Gilad, CEO of Aprea Therapeutics

bexib
By bexib 0 Min Read

Gilad discusses how this method could be used to treat a variety of cancers without exposing patients to the side effects of chemotherapy.

You Might Also Like

How AI is advancing drug reinvention: Q&A with Dr. Friso Postma

The Evolution of Verification: Insights and Trends for 2024

Health In Tech Announces New Partnership to Expand Health Insurance Options for Employers in Southern Ohio

CalPERS Names Blue Shield of California as Sole Health Plan Provider

Pharma Pulse 5/20/24: The future of RBQM implementation, AI to revolutionize pregnancy care and cancer screening, and more

Share This Article
Previous Article Bitcoin’s role as collateral in real estate development financing
Next Article GLP-1 Therapy Significantly Increases Visceral Adipose Tissue Metabolic Activity in Patients with Obesity, Obstructive Sleep Apnea
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Late onboarding promotes clients’ losses at Singapore banks.
Fintech
The gorgeous spa Hotelgal Goma Resort will join the elegant hotel collection as the first member of the North Ireland
Hospitality & Tourism
Peter Navalo says, necessary for Trump’s economic success vision
Manufacturing
What you need to know about Singapore’s most common payment fraud
Fintech